Abelacimab, formerly known as MAA868, represents a novel approach to treating thrombosis. This antithrombotic agent is a targeted monoclonal immunoglobulin that blocks the integrin αIIbβ3, a essential player in https://alexiamdhn552620.mpeblog.com/73636220/abelacimab-maa868-a-deep-analysis-into-the-new-thrombosis-treatment